CD274 and cancer: While blockade of the PD-1/PD-L1 axis has led to remarkable advances in cancer immunotherapy (31), the overall response rate among patients with advanced cancers remains low, largely due to immunosuppressive signaling pathways or insufficient immune cell infiltration (1).